Carnegie Capital Asset Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,340 shares of the company’s stock after acquiring an additional 2,311 during the period. Johnson & Johnson makes up approximately 1.1% of Carnegie Capital Asset Management LLC’s holdings, making the stock its 18th largest holding. Carnegie Capital Asset Management LLC’s holdings in Johnson & Johnson were worth $29,126,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Magnolia Capital Management Ltd. lifted its stake in shares of Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. Now owns 11,162 shares of the company’s stock shares valued at $1,978,000 after purchasing an additional 55 during the period. Capital Investment Counsel Inc increased its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after purchasing an additional 59 shares in the last quarter. Beaton Management Co. Inc. boosted its stake in shares of Johnson & Johnson by 0.3% during the 4th quarter. Beaton Management Co. Inc. Now owns 22,250 shares of the company’s stock worth $3,806,000 after buying an additional 60 shares during the last quarter. Corsicana & Co. lifted its stake in Johnson & Johnson by 0.4% in the 1st quarter. Corsicana & Co. Now owns 15,553 shares of the company’s stock valued at $2,756,000 after purchasing an additional 60 during the last quarter. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.
In related news, insider William Hait sold 29,699 shares of the stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders have sold 78,161 shares of company stock worth $13,895,302 in the last quarter. Company insiders own 0.35% of the company’s stock.
A number of research firms have weighed in on JNJ. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Bank of America assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating for the company. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market performer” rating and upped their objective price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Finally, The Goldman Sachs Group upped their objective price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $190.50.
Shares of NYSE:JNJ opened at $179.66 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a market capitalization of $472.76 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.42 and a beta of 0.66. The firm’s 50 day simple moving average is $177.65 and its two-hundred day simple moving average is $173.20.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping the consensus estimate of $2.60 by $0.07. The firm had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 dividend on an annual basis and a yield of 2.52%. Johnson & Johnson’s payout ratio is 60.92%.
About Johnson & Johnson (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.